Seedlabs

DoseCurve VR: Objective Medication-Titration Tracker for Pediatric ADHD

A short, repeatable VR classroom attention test given at each ADHD medication titration visit, producing an objective per-child dose-response curve. Prescribers adjust stimulant doses on measured attention data instead of rating scales alone.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderPediatric ADHD medication management (stimulant titration and follow-up)

Concept

A monitoring product for the medication-titration phase of ADHD care. At baseline and at each follow-up visit (e.g., weeks 1, 4, and 8 after starting or changing a stimulant), the child completes the same brief VR classroom CPT; the software auto-compares attention metrics across sessions and renders a per-child dose-response curve — attention performance versus dose and time — alongside parent and teacher ratings. The wedge is a single capability: objective, longitudinal measurement of treatment response. It deliberately does not diagnose and does not deliver therapy; it gives prescribers a repeatable, ecologically valid readout to answer 'is this dose working?' in one visit. Delivered as software plus commodity headsets to child-psychiatry practices, developmental pediatrics, and pediatric behavioral-health telehealth, with the repeated-measurement protocol validated in post-launch studies.

Why now

The overview [0] shows VR-CPTs are the field's workhorse measure — used in 70% of 30 studies covering 2,378 children aged 4-18 — with reported superior efficiency and validity versus traditional CPTs, and 83% (8/9) of studies targeting symptom management reported benefit, indicating VR-based tasks are clinically sensitive rather than technical demos. Current management evidence [6] describes ADHD as a chronic, fluctuating condition requiring sustained, individualized care with frequent medication adjustment, yet titration today relies largely on subjective rating scales collected weeks apart. With the evidence base at prototype stage but directionally consistent (93% of studies met at least one clinical objective), the natural commercialization step is a focused, repeatable measurement product aimed at the highest-frequency decision in ADHD care — dose adjustment.

Written by GLM · 14 Oct 2026

AI assessment

Backed by 2 papers84

A focused, high-utility tool that transforms VR-CPTs from a one-time diagnostic event into a longitudinal titration tool, solving a specific clinical pain point in ADHD medication management.

Evidence strength
4/5
The overview confirms VR-CPTs are the field's workhorse with superior validity over traditional tests, and the management paper confirms the chronic, fluctuating nature of ADHD requiring frequent titration.
Market pull
4/5
Pediatric psychiatrists and behavioral health clinics have a high-frequency need for objective data during titration to replace subjective, lagging rating scales.
Novelty & moat
3/5
While it uses the same mechanism as the 'Virtual Classroom CPT' (diagnostic), it pivots the value proposition from diagnosis to longitudinal dose-response tracking, filling a distinct clinical gap.
Feasibility
5/5
The core technology (VR-CPT) is already established in research; the MVP simply requires a longitudinal data visualization layer and a repeatable protocol.
Wedge clarity
5/5
The wedge is exceptionally sharp: a single, repeatable test used specifically for the 'is this dose working?' question during titration visits.
Simplicity / focus
5/5
The idea avoids 'platform creep' by explicitly rejecting diagnosis and therapy, focusing solely on objective measurement for dose adjustment.

Scored by Gemma 4 · 14 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Akili Interactivecompany

    Maker of the FDA-cleared EndeavorRx digital ADHD treatment; a standardized objective attention tracker gives it a defensible outcome measure for treatment-response conversations with payers and clinicians.

  • Brightlinecompany

    This pediatric behavioral-health provider manages ADHD including medication; brief VR testing at visits (or with mailed headsets) adds objective follow-up data to its virtual care model.

  • Children's Hospital of Philadelphiaorganization

    Its large ADHD clinical and research programs would gain objective titration data that improves care and builds standardized longitudinal datasets for research.

  • American Academy of Child and Adolescent Psychiatry (AACAP)organization

    Its members titrate stimulants across many patients; an objective dose-response readout supports evidence-based prescribing decisions and clearer documentation.

Research it builds on

  1. The usefulness of virtual, augmented, and mixed reality technologies in the diagnosis and treatment of attention deficit hyperactivity disorder in children: an overview of relevant studies
    Saeideh Goharinejad, Samira Goharinejad, Sadrieh Hajesmaeel-Gohari et al. · 2022 · 91 citations
    All ideas from this paper →
  2. Advances in the management of ADHD in children and adolescents
    Philippe Robaey, Maria Rogers, Russell James Schachar · 2026 · 2 citations
    All ideas from this paper →
Leave feedback
feasibility